CIGB-258, inhibitor peptide of hyperinflammation in COVID-19 patients
Keywords:
CIGB-258, Jusvinza, COVID-19, hyperinflammation, cytokine stormAbstract
Introduction. CIGB-258 is a peptide, whose mechanism of action has been associated with the inhibition of inflammation. This paper aims to demonstrate that CIGB-258 reduces hyperinflammation in COVID-19 patients. Methods. Pharmacokinetic and biodistribution profiles of the peptide labeled with iodine 125 [125I] were studied in Lewis rats. Thirteen critical COVID-19 patients and nine severe ones were included and treated, according to the protocol established (RPCEC00000313). Serum samples were obtained before and after treatment with CIGB-258, for the determination of biomarkers of inflammation. Results. Maximum concentration of peptide in blood from rats was at 0,5 to 1 h; and the half-life (t½) was calculated to be 6,3 to 6,9 hours. 48 h after the treatment with CIGB-258, clinical, radiological, and ventilation improvement was observed in all patients. C-reactive protein (CRP) levels significantly decreased after 72 h. CRP levels were inversely associated with oxygen uptake efficiency in the mechanical ventilation cohort in critical patients. Laboratory tests associated with hyperinflammation included white blood cell count with differential, ferritin, lactate dehydrogenase and calprotectin, which were gradually normalized. CIGB-258 led to a significant reduction of IL-6, TNF α and IL-10. Conclusion: CIGB-258 induced a clinical and radiological improvement in the patients, according with its pharmacokinetic and biodistribution profile. This improvement was associated with a decrease in biomarkers of systemic inflammation.Downloads
Published
How to Cite
Issue
Section
License
The journal Anales de la Academia de Ciencias de Cuba protects copyright, and operates with a Creative Commons License 4.0 (Creative Commons Attribution-NonCommercial License 4.0). By publishing in it, authors allow themselves to copy, reproduce, distribute, publicly communicate their work and generate derivative works, as long as the original author is cited and acknowledged. They do not allow, however, the use of the original work for commercial or lucrative purposes.
The authors authorize the publication of their writings, retaining the authorship rights, and assigning and transferring to the magazine all the rights protected by the intellectual property laws that govern in Cuba, which imply editing to disseminate the work.
Authors may establish additional agreements for the non-exclusive distribution of the version of the work published in the journal (for example, placing it in an institutional repository or publishing it in a book), with recognition of having been first published in this journal.
To learn more, see https://creativecommons.org
